Key Points
- Director Jung Choi bought 33,000 shares of Annexon at an average price of $4.19 on Dec. 1, a $138,270 purchase disclosed in an SEC Form 4.
- ANNX opened at $4.28 with a 52‑week range of $1.28–$5.66, a market cap of about $512M and a negative P/E (-3.04); its 50‑ and 200‑day moving averages are $3.35 and $2.73, respectively.
- Analyst views are mixed — consensus rating is a Hold with a $17.33 price target, while the company recently missed quarterly EPS (-$0.37 vs. -$0.34) and is forecast to report about -0.96 EPS for the fiscal year.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson purchased 4,115 shares of the company's stock in a transaction on Monday, December 1st. The stock was acquired at an average cost of $4.47 per share, for a total transaction of $18,394.05. Following the completion of the transaction, the director owned 50,290 shares in the company, valued at approximately $224,796.30. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Annexon Stock Performance
Shares of ANNX traded up $0.03 during mid-day trading on Thursday, hitting $4.31. The company's stock had a trading volume of 257,162 shares, compared to its average volume of 1,793,854. The stock's 50-day moving average is $3.35 and its two-hundred day moving average is $2.73. The firm has a market capitalization of $515.02 million, a PE ratio of -3.05 and a beta of 1.20. Annexon, Inc. has a one year low of $1.28 and a one year high of $5.66.
Annexon (NASDAQ:ANNX - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Analysts expect that Annexon, Inc. will post -0.96 EPS for the current fiscal year.
Institutional Trading of Annexon
Large investors have recently made changes to their positions in the business. Citizens Financial Group Inc. RI lifted its position in Annexon by 14.3% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company's stock worth $122,000 after buying an additional 5,000 shares in the last quarter. CWM LLC raised its stake in shares of Annexon by 32.4% in the third quarter. CWM LLC now owns 23,488 shares of the company's stock worth $72,000 after acquiring an additional 5,754 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of Annexon by 19.9% during the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock valued at $73,000 after purchasing an additional 6,136 shares during the last quarter. Comerica Bank increased its holdings in shares of Annexon by 26.4% in the third quarter. Comerica Bank now owns 32,357 shares of the company's stock valued at $99,000 after purchasing an additional 6,750 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock worth $193,000 after buying an additional 7,553 shares in the last quarter.
Analysts Set New Price Targets
A number of brokerages have recently commented on ANNX. Wells Fargo & Company upped their price objective on shares of Annexon from $14.00 to $27.00 and gave the company an "overweight" rating in a research report on Wednesday, November 19th. Zacks Research raised Annexon from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Annexon in a report on Wednesday, October 8th. Finally, HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Annexon in a research note on Friday, August 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Annexon presently has an average rating of "Hold" and an average price target of $17.33.
Check Out Our Latest Report on Annexon
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
